LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

30-Second COVID-19 Breathalyzer Test Could Be a Game-Changer

By LabMedica International staff writers
Posted on 13 Oct 2020
Print article
Illustration
Illustration
India and Israel are jointly developing a new rapid COVID-19 testing kit that will simply require an individual to blow into a tube and deliver results in less than a minute, making the test a real game-changer.

Israeli Ambassador to India Ron Malka told the Indian news agency PTI that the test should be ready in “a matter of days.” In the operation dubbed “Open Skies,” inspired by the belief that the testing kit will enable the world to begin opening the skies, Israel has sent a high level research delegation to India for conducting a series of "final stages of testing" to develop the rapid COVID-19 testing kit. The team of researchers has conducted trials using a large number of samples in India for four different kinds of technologies having the capabilities to rapidly detect SARS-CoV-2, namely sound waves, breathalyzers based on terahertz waves, isothermic identification and checking polyamino acids. According to Malka, each test has passed different stages of evaluation. The test would be extremely cheap to perform, as it would deliver results locally and eliminate logistics as well as the cost involved for sending samples to the laboratory. Malka said that India was likely to become the manufacturing headquarters for the new rapid test kit and experts from both the countries also planned to jointly develop COVID-19 vaccines.

"It will be good news for the entire world. Until we manage to immunize the entire population, this joint operation, which we had named 'open skies', would literally open the skies in terms of international travel and other economic activities as this can be used at airports and other places by requiring a person just to blow into a tube and the result would be available in 30-40-50 seconds," Malka told PTI.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more